Search research articles
Contact Us
Filters
Showing results (91-100 of 111) with videos related to
Page
of 12
Sort By:
Annals of Clinical and Translational Neurology
|
January 11, 2022
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS
Jonathan S Katz, Jeffrey D Rothstein, Merit E Cudkowicz, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
February 24, 2021
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study
Stacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.
Therapeutic Advances in Neurological Disorders
|
April 19, 2024
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study
James F Howard, Saskia Bresch, Constantine Farmakidis, et al.
JAMA Neurology
|
February 9, 2026
Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis
Timothy M Miller, Merit E Cudkowicz, Pamela J Shaw, et al.
Journal of Parkinson'S Disease
|
December 24, 2019
The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository
Ziv Gan-Or, Trisha Rao, Etienne Leveille, et al.
The Lancet. Neurology
|
July 26, 2024
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study
Leonard H van den Berg, Jeffrey D Rothstein, Pamela J Shaw, et al.
The New England Journal of Medicine
|
July 9, 2020
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
Timothy Miller, Merit Cudkowicz, Pamela J Shaw, et al.
Muscle & Nerve
|
April 16, 2022
Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy
Jeffrey M Statland, Craig Campbell, Urvi Desai, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
July 6, 2025
Toward therapeutic trials in primary lateral sclerosis
Erica Scirocco, Matti D Allen, Elisa Giacomelli, et al.
Journal of Neuromuscular Diseases
|
February 6, 2026
A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study
Nicol C Voermans, Jeffrey M Statland, Lawrence J Hayward, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 111) with videos related to
Sort By:
Page
of 12
Annals of Clinical and Translational Neurology
|
January 11, 2022
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS
Jonathan S Katz, Jeffrey D Rothstein, Merit E Cudkowicz, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
February 24, 2021
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study
Stacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.
Therapeutic Advances in Neurological Disorders
|
April 19, 2024
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study
James F Howard, Saskia Bresch, Constantine Farmakidis, et al.
JAMA Neurology
|
February 9, 2026
Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis
Timothy M Miller, Merit E Cudkowicz, Pamela J Shaw, et al.
Journal of Parkinson'S Disease
|
December 24, 2019
The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository
Ziv Gan-Or, Trisha Rao, Etienne Leveille, et al.
The Lancet. Neurology
|
July 26, 2024
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study
Leonard H van den Berg, Jeffrey D Rothstein, Pamela J Shaw, et al.
The New England Journal of Medicine
|
July 9, 2020
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
Timothy Miller, Merit Cudkowicz, Pamela J Shaw, et al.
Muscle & Nerve
|
April 16, 2022
Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy
Jeffrey M Statland, Craig Campbell, Urvi Desai, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
July 6, 2025
Toward therapeutic trials in primary lateral sclerosis
Erica Scirocco, Matti D Allen, Elisa Giacomelli, et al.
Journal of Neuromuscular Diseases
|
February 6, 2026
A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study
Nicol C Voermans, Jeffrey M Statland, Lawrence J Hayward, et al.
Page
of 12